Please type a plus sign (+) inside this bc [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete If Known	
Application Number	**new Application**
Filing Date	not yet assigned
First Named Inventor	**Weikert, et al.**
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	R0087B-REG

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,382,595		Minami et al.	Jan. 17, 1995	
	A2	5,177,089		Minami et al.	Jan. 5, 1993	
	A3	5,047,417		Minami et al.	Sept. 10, 1991	
	A4	5,607,953		Minami et al.	Mar. 4, 1997	
	A5	4,748,182		Hilbert et al.	May 31, 1988	
	A6	4,880,802		Schohe et al.	Nov. 14, 1989	
	A7	5,298,513		Schohe et al.	Mar. 29, 1994	
	A8	4,584,293		Reiffen et al.	Apr. 22, 1986	
	A9	5,118,704		Minaskanian et al.	Jun. 2, 1992	
	A10	5,545,755		Lin et al.	Aug. 13, 1996	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	WO	99/43657	PCT	F.Hoffmann-La Roche	Sept., 2 1999		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark hee if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Doc.#113580

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	**New Application**
Filing Date	not yet assigned
First Named Inventor	**Weikert, et al.**
Group Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	R0087B-REG

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	HOMAN et al., "Structural Analogues of 5-Ome-BPAT: Synthesis and Interactions with Dopamine D_2, D_3, and Serotonin 5-HT_{1A} Receptors", Bioorg. Med. Chem., (1999), pp. 1111-1121, vol. 7(6)	
	C2	GLENNON et al, "N-(Phthalimidoalkyl) Derivatives of Serotonergic Agents: A Common Interaction at 5-HT_{1A} Serotonin Binding Sites?", J.Med. Chem., (1989), pp. 1921-1926, vol. 32	
	C3	EHLERT, et al., "Subtypes of the Muscarinic Receptor in Smooth Muscle", Life Sciences, (Minireview), (1997), pp. 1729-1740, vol. 61, No. 18	
	C4	HEDGE, et al., "Muscarinic Receptor Subtypes Modulating Smooth Muscle Contractility in the Urinary Bladder", Life Sciences, (1999), pp. 419-428, 64, Nos. 6/7	
	C5	EGLEN, et al., "Muscarinic acetylcholine receptor subtypes in smooth muscle", Trends. Pharmacol. Sci., (1994), pp. 114-119, vol. 15	
	C6	EGLEN, et al, "Muscarinic receptor subtypes and smooth muscule function", Pharmacol. Rev., (1996), pp. 531-565, vol. 48, No.4	
	C7	NILVEBRANT, et al., "Tolterodine – A new Bladder Selective Muscarinic Receptor Antagonist: Preclinical Pharmacological and Clinical Data", Life Sciences, (1997), pp. 1129-1136, vol. 60	
	C8	ALABASTER, "Discovery & Development of Selective M_3 Antagonists for Clinical Use", Life Sciences, (1997), pp. 1053-1060, vol. 60, Nos. 13/14	
	C9	OSAYU, et al, "Urinary Bladder-selective Action of the New Antimuscarinic Compound Vamicamide", Drug Res., (1994) , pp. 1242-1249, vol. 44(II), No. 11	
	C10	HOMMA, et al, "Randomized Double-Blind Study to Compare Clinical Efficacy of Temiverine and Propiverine for Unstable Bladder and Detrusor Hyperreflexia", Neurology and Urodynamics,–**Abstract**, (1997), pp. 345-346, vol. 16	
	C11	EGLEN AND HEGDE, "Selective modulation of muscarinic receptor subtypes: therapeutic potential", Emerging Drugs,– Chapter 4, (1998), pp. 67-79, vol. 3, Ashley Publications	
	C12	EGLEN, et al, "Muscarinic receptor ligands and their therapeutic potential", Curr. Opin. Chem. Biol. (1999), pp. 426-432, vol. 3, Elsevier Science	
	C13	CAULFIELD, et al, "International Union of Pharmacology. XVII. Classification of Muscarinic Acetylcholine Receptors", Pharmacological Reviews, (1998), pp. 279-290, vol. 50(2)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] if English language Translation is attached